Status:
COMPLETED
Air-Q® SP Versus Williams Intubating Airway for Single-Operator FOI
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Intubation; Difficult or Failed
Laryngeal Masks
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The air-Q and air-Q SP are commercially-available supraglottic airways (SGAs) that can be used for primary airway maintenance or as a conduit for FOI, as can be the Williams, Ovassapian, and Berman In...
Detailed Description
Despite the introduction of videolaryngoscopes, flexible bronchoscopic intubation (FBI), also known as fiberoptic intubation (FOI), remains a critical method for achieving tracheal intubation in patie...
Eligibility Criteria
Inclusion
- Adult patients (≥18 years);
- The patient is scheduled for an elective surgery or procedure that will take place in the UWHC main operating room, outpatient surgical center, or ambulatory procedure center; and
- The patient's primary anesthesia care team has planned for general anesthesia with orotracheal intubation for airway maintenance.
Exclusion
- The patient is \< 18 years of age;
- The patient is non-English speaking;
- The patient is known or believed to be pregnant;
- The patient is a prisoner;
- The patient has impaired decision-making capacity;
- The patient is at increased risk for aspiration, including non-fasted or emergency surgery, and cases of uncontrolled gastroesophageal reflux disease, hiatal hernia, gastroparesis, esophageal dysmotility, prior esophagectomy, and/or emesis within twenty-four hours of the surgery or procedure;
- The patient has limited mouth opening or oropharyngeal anatomy making successful placement of the study airway conduit unlikely;
- The patient has airway exam features, a medical condition, or a past airway management history, which prompts the attending anesthesiologist to plan to maintain spontaneous ventilation during tracheal intubation;
- The patient pre-operatively is requiring supplemental oxygen;
- The patient has moderate to severe cardiac disease, as evidenced by a left ventricular ejection fraction of ≤ 50% on the most recent echocardiogram, severe aortic valve stenosis, atrial fibrillation with a resting pre-operative heart rate of ≥ 90 beats per minute, and/or known, multi-vessel coronary artery, managed conservatively with medical management or by intervention with multiple coronary artery stents or coronary bypass grafting; and
- The patient has an allergy to glycopyrrolate.
Key Trial Info
Start Date :
June 11 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 8 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03247803
Start Date
June 11 2018
End Date
March 8 2019
Last Update
March 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin Hopital and Clinics
Madison, Wisconsin, United States, 53792